News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Vertex Pharmaceuticals Incorporated Hepatitis C Drug Meets Study Goal
August 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass. - Vertex Pharmaceuticals Inc. said late Thursday its hepatitis C drug candidate telaprevir was both safe and prompted a response in patients during a midstage study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
·
3 min read
·
Tristan Manalac
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
·
3 min read
·
Tristan Manalac
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
June 24, 2025
·
2 min read
·
Tristan Manalac
